VIDEO: Gene therapy shows promising disease control for wet AMD in clinical trials
Click Here to Manage Email Alerts
FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress, Carl D. Regillo, MD, discusses promising results for the Ixo-vec gene therapy for neovascular age-related macular degeneration.
Ixo-vec (ixoberogene soroparvovec, Adverum Biotechnologies), formerly referred to as ADVM-022, is being investigated in both the phase 2 LUNA and phase 1 OPTIC studies.
“We’re seeing better tolerance to this form of intravitreal gene therapy and excellent disease control, and the OPTIC phase 1 extension program is showing ongoing excellent control now out through 3 years,” he said.
Collapse
Regillo C. Ixo-vec (ixoberogene soroparvovec) intravitreal gene therapy for nAMD: Preliminary data from the phase 2 LUNA study and 3-year results from the phase 1 OPTIC extension trial. Presented at: Retina World Congress; May 9-12, 2024; Fort Lauderdale, Florida.
Click Here to Manage Email Alerts